Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod, Retinal Dystrophy Rod Progressive, Retinitis Pigmentosa
Conditions
Keywords
Retinitis Pigmentosa, Retinitis Pigmentosa Type 11, RP11, PRPF31, Retinal Dystrophy, PRPF31 Mutation-Associated Retinal Dystrophy
Brief summary
The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11. Assessments will be completed to measure and evaluate structural and functional visual changes including those impacting patient quality of life associated with this inherited retinal condition and observing how these changes evolve over time.
Detailed description
This is a multi-center, longitudinal, prospective observational natural history study of participants with a molecularly confirmed mutation in PRPF31. Approximately 50 participants (100 eyes) at approximately 5 sites will be enrolled into a uniform protocol for follow-up and evaluations. Each participant's medical record will be reviewed for historical information, and clinical data will be recorded in a secure database. Natural history data will be collected prospectively and will include ophthalmic exams, imaging studies, electrophysiological testing, functional mobility evaluations, and questionnaires. Assessments will be conducted in a standardized protocol every 16 weeks ± 4 weeks for the first year and then every 24 weeks ± 4 weeks for up to approximately 4 years after each participant's baseline visit (Visit 2).
Interventions
None listed
Sponsors
PYC Therapeutics
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
10 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Participants must meet all of the following in order to be enrolled into the study: 1. Male or female, ≥ 10 years of age at baseline (Visit 2). 2. Have a clinical and molecular diagnosis of PRPF31 mutation-associated retinal dystrophy. 3. If ≥ 18 years of age, understand the language of the informed consent and are willing and able to provide written informed consent prior to any study procedures. If \< 18 years of age, are willing to assent to study participation in writing and have a legally authorized representative provide written informed consent on your behalf. 4. Are willing to comply with the instructions and attend all scheduled study visits.
Exclusion criteria
Participants or, in the case of ocular-specific criteria, individual eyes with any of the following will not be allowed to participate in this study: 1. Have any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study (e.g., infection, uncontrolled elevated blood pressure, cardiovascular disease, or glycemic control issues) or put the participant at risk due to study procedures. 2. Have mutations in genes that cause autosomal dominant retinitis pigmentosa (adRP), X-linked retinitis pigmentosa (XLRP), or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than PRPF31 mutations. 3. Have used anti-vascular endothelial growth factor (VEGF) agents or corticosteroid injections or implants. 4. Have had Ozurdex® implants placed within 3 months or Retisert® or Iluvien® implants placed within 3 years prior to Visit 2. 5. Within 3 months prior to Visit 2, have undergone any vitreoretinal surgery (scleral buckle, pars plana vitrectomy, retrieval of a dropped nucleus or intraocular lens, radial optic neurotomy, sheathotomy, cyclodestructive procedures or multiple filtration surgeries \[2 or more\], etc.) or any other ocular surgery. 6. Have ocular media opacity or poor pupillary dilation that prohibits quality ophthalmic evaluation or photography. 7. Have used any investigational drug or device within 90 days or 5 estimated half-lives of Visit 2, whichever is longer, or plan to participate in another study of drug or device during the study period. 8. Have received any prior cell or gene therapy for a retinal condition. 9. Have a history of illicit drug use or alcohol dependency.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in Best Corrected Visual Acuity (BCVA) | Baseline through Year 4 | BCVA letter score utilizing ETDRS (Early Treatment Diabetic Retinopathy Study) or BRVT (Berkeley Rudimentary Vision Test) for patients not able to see letters |
| Change in Best Corrected Low Luminance Visual Acuity (LLVA) | Baseline through Year 4 | Best corrected LLVA letter score measured using the ETDRS charts and a special light filter lens |
| Change from Baseline in Retinal Thickness | Baseline through Year 4 | Retinal thickness is measured using spectral domain optical coherence tomography (SD-OCT), as measured by the central reading center |
| Change from Baseline in Ellipsoid Zone (EZ) Area | Baseline through Year 4 | Change in EZ area measured using spectral domain optical coherence tomography (SD-OCT), as measured by the central reading center |
| Change from Baseline in Ellipsoid Zone (EZ) Volume | Baseline through Year 4 | Change in EZ volume measured using spectral domain optical coherence tomography (SD-OCT), as measured by the central reading center |
| Change from Baseline in Visual Field Sensitivity | Baseline through Year 4 | Visual field sensitivity measured by static perimetry with topographic analysis-Hill of Vision conducted by the central reading center |
| Change from Baseline in Mean Macular Sensitivity | Baseline through Year 4 | Mean macular sensitivity measured on guided microperimetry |
| Change from Baseline in Fixation Stability | Baseline through Year 4 | Fixation stability as measured by Macular Integrity Assessment (MAIA) microperimeter |
| Change from Baseline in Full Field Retinal Sensitivity | Baseline through Year 4 | Dark-adapted visual sensitivity via full-field stimulus threshold (FST) measurement |
| Change from Baseline in Electrical response | Baseline through Year 4 | Electrical response measured using Full-field electroretinogram (ERG) with specific stimuli |
| Characterization of Changes of the Retina with Fundus Photography | Baseline through Year 4 | Abnormalities captured by fundus photography |
| Change from Baseline in Area of Fundus Autofluorescence (FAF) | Baseline through Year 4 | Area of hypo-autofluorescence captured by fundus autofluorescence (FAF) |
| Change from Baseline in Functional Vision | 3 times prior to Month 4 | Functional vision is measured with a functional mobility course (Ora-VNC™) score |
| Change in Patient Reported Outcome Measures using Michigan Retinal Degeneration Questionnaire (MRDQ) | Baseline through Year 4 | Responses on the MRDQ, a validated patient reported outcomes measure designed in accordance with U.S. FDA guidelines, specifically for conditions of inherited retinal degeneration (IRDs) |
| Change in Patient Reported Outcome Measures using Patient Global Impression of Severity (PGI-S) scale | Baseline through Year 4 | Responses on the PGI-S to assess severity of the patient's condition |
| Change in Patient Reported Outcome Measures using Patient Global Impression of Change (PGI-C) scale | Baseline through Year 4 | Responses on the PGI-C to assess change of the patient's condition |
| Genomic Analysis for Study Eligibility | Screening | Whole exome genomic analysis |
| Ocular Adverse Events (AEs) | Screening through Year 4 | Frequency of ocular adverse events (AEs) |
Countries
Australia, United States
Contacts
STUDY_CHAIRSreenivasu Mudumba, PhD
PYC Therapeutics
Outcome results
None listed